glp-1 agonist comparison chart glp 1 equivalency Antagonists Increase Plan Drug Spend Comparison of adverse effects between

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Needles with a sharp, well-designed bevel reduce pain and trauma during insertion

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

15(19) :4701 Bahaa Eldeen NM et al